ClinicalTrials.gg
Sign In
CompletedNCT05234203Updated Dec 6, 2022

The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age

An interventional study of HTB Rejuvenate in Immunity Disorders, Aging and Inflammation, sponsored by Big Bold Health, PBC. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-06.

Sponsored by Big Bold Health, PBC · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.

Read the detailed description

The objective of this study is to understand the impact of a polyphenol-rich supplement on measurements of epigenetic immune age and immune cell patterns germane to immune age over a 90-day period. The primary objective of this trial is to assess the effects of the supplement, HTB Rejuvenate™, on immune age markers. The secondary objective of this trial is to assess the effects of the supplement, HTB Rejuvenate, on leukocyte immune profiles including T cell subsets and granulocytes.

02

Conditions studied

  • Immunity Disorders
  • Aging
  • Inflammation

Keywords

  • Inflammaging
  • Immunosenescence
  • Polyphenol
  • Phytochemical
  • Phytonutrient
  • Tartary buckwheat
  • Fagopyrum tataricum
03

In context

Immune System Diseases

288 studies on the registry are indexed under Immune System Diseases; 80 are open to participants now.

This study's enrollment of 50 is below the median of 71 across 194 interventional studies indexed under Immune System Diseases.

Browse Immune System Diseases studies →

Lead sponsor

This is the only study on the registry with Big Bold Health, PBC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women of any ethnicity.
  • Age Range - 18 - 85 (inclusive)
  • Participant must be able to comply with treatment plan and laboratory tests including ability and willingness to perform home venous blood draw using Tasso device.
  • Participant must be able to read, write and speak English fluently
  • Participant must have an established primary care provider
  • Participant must be willing and able to consume 4 capsules per day throughout the duration of study period

Exclusion criteria

Exclusion Criteria:

  • History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  • Known immune system issues or immunodeficiency disease
  • History of viral illness which could be reactivated by immune downregulation
  • Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
  • Diagnosis of a transient ischemic attack in the 6 months prior to screening
  • Participants infected with hepatitis C or HIV
  • Body Mass Index (BMI) greater than or equal to 40 kilograms per meter squared
  • Presence of active infection in previous 4 weeks
  • Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the Clinical Investigator would render a participant unsuitable to participate in the study
  • Unable or unwilling to provide required blood sample for testing
  • Current or previous use of known prescription immunomodulating products (e.g. glucocorticoids, tumor necrosis factor (TNF)-alpha inhibitors) in the month prior to the start of the trial.
  • Taking a concentrated polyphenol-focused supplement in the month prior to the start of the trial (e.g., quercetin, Epigallocatechin gallate (EGCG), resveratrol, curcumin, berberine, soy isoflavones, rutin, luteolin fisetin) or products that contain Tartary buckwheat
  • A known history of blood dyscrasias including coagulopathy
  • Current use of prescription anticoagulant medications
  • Current pregnancy, planned attempts to conceive during study period or sexually active females not using contraception, as well as lactating/nursing females
  • Current job that requires night-shift work
  • Known allergy to polyphenolics
  • Known allergy to buckwheat or Tartary buckwheat
  • Investors or immediate family of investors in Big Bold Health
  • Any person deemed by Clinical Investigator as low likelihood of complying with study protocol (e.g. evidence of history of non-compliance, history of poor follow-up, multiple or complex scheduling conflicts).
  • Planned surgical procedure during study period
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    HTB Rejuvenate

    4 capsules of study interventional supplement delivered as 2 capsules two times a day for 90 days.

    Dietary Supplement: HTB Rejuvenate

Interventions

  • Dietary supplementHTB Rejuvenate

    90 days of BID dosing of 2 capsules of HTB Rejuvenate

06

What researchers measure

Primary outcomes

  1. Epigenetic immune age

    Measurement of changes in methylation patterns on DNA related to immune age using the TruAge Biological Age test, which tests for methylation at 850,000 separate locations on DNA

    Time frame: Change from baseline to 90 days

Secondary outcomes

  1. Leukocyte profiling

    Relative numbers of T cell subsets and granulocytes obtained using deconvolution analysis from epigenetic data obtained from the TruAge Biological Age test, which tests for methylation at 850,000 separate locations on DNA

    Time frame: Change from baseline to 90 days

07

Study locations

1 site
  • Big Bold Health PBC
    Bainbridge Island, Washington 98110-1793, United States
08

References and documents

Publications

  • Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017 Apr 1;389(10076):1323-1335. doi: 10.1016/S0140-6736(16)32381-9. Epub 2017 Feb 22. PubMed 28236464 ↗
  • Gensous N, Garagnani P, Santoro A, Giuliani C, Ostan R, Fabbri C, Milazzo M, Gentilini D, di Blasio AM, Pietruszka B, Madej D, Bialecka-Debek A, Brzozowska A, Franceschi C, Bacalini MG. One-year Mediterranean diet promotes epigenetic rejuvenation with country- and sex-specific effects: a pilot study from the NU-AGE project. Geroscience. 2020 Apr;42(2):687-701. doi: 10.1007/s11357-019-00149-0. Epub 2020 Jan 24. PubMed 31981007 ↗
  • Fitzgerald KN, Hodges R, Hanes D, Stack E, Cheishvili D, Szyf M, Henkel J, Twedt MW, Giannopoulou D, Herdell J, Logan S, Bradley R. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging (Albany NY). 2021 Apr 12;13(7):9419-9432. doi: 10.18632/aging.202913. Epub 2021 Apr 12. PubMed 33844651 ↗
  • Stojkovic L, Zec M, Zivkovic M, Bundalo M, Boskovic M, Glibetic M, Stankovic A. Polyphenol-Rich Aronia melanocarpa Juice Consumption Affects LINE-1 DNA Methylation in Peripheral Blood Leukocytes in Dyslipidemic Women. Front Nutr. 2021 Jun 17;8:689055. doi: 10.3389/fnut.2021.689055. eCollection 2021. PubMed 34222308 ↗
  • Sharma, R., & Padwad, Y. (2020). Perspectives of the potential implications of polyphenols in influencing the interrelationship between oxi-inflammatory stress, cellular senescence and immunosenescence during aging. Trends in Food Science & Technology, 98, 41-52. https://doi.org/10.1016/j.tifs.2020.02.004
  • Santos JC, Ribeiro ML, Gambero A. The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients. Front Physiol. 2021 Jan 12;11:612268. doi: 10.3389/fphys.2020.612268. eCollection 2020. PubMed 33584335 ↗
  • Bahramsoltani R, Ebrahimi F, Farzaei MH, Baratpourmoghaddam A, Ahmadi P, Rostamiasrabadi P, Rasouli Amirabadi AH, Rahimi R. Dietary polyphenols for atherosclerosis: A comprehensive review and future perspectives. Crit Rev Food Sci Nutr. 2019;59(1):114-132. doi: 10.1080/10408398.2017.1360244. Epub 2017 Sep 25. PubMed 28812379 ↗
  • Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev. 2016 Jul;17(7):573-86. doi: 10.1111/obr.12409. Epub 2016 Apr 15. PubMed 27079631 ↗
  • Sharma R, Padwad Y. Plant-polyphenols based second-generation synbiotics: Emerging concepts, challenges, and opportunities. Nutrition. 2020 Sep;77:110785. doi: 10.1016/j.nut.2020.110785. Epub 2020 Mar 2. PubMed 32283341 ↗
  • da Silveira Vasconcelos, M., de Oliveira, L. M. N., Mota, E. F., de Siqueira Oliveira, L., Gomes-Rochette, N. F., Nunes-Pinheiro, D. C. S., ... & de Melo, D. F. (2020). Consumption of rich/enrich phytonutrients food and their relationship with health status of population. In Phytonutrients in Food (pp. 67-101). Woodhead Publishing. https://doi.org/10.1016/B978-0-12-815354-3.00006-X
  • Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr. 2003 Sep;78(3 Suppl):517S-520S. doi: 10.1093/ajcn/78.3.517S. PubMed 12936943 ↗
  • Huda MN, Lu S, Jahan T, Ding M, Jha R, Zhang K, Zhang W, Georgiev MI, Park SU, Zhou M. Treasure from garden: Bioactive compounds of buckwheat. Food Chem. 2021 Jan 15;335:127653. doi: 10.1016/j.foodchem.2020.127653. Epub 2020 Jul 24. PubMed 32739818 ↗
  • Dziedzic K, Gorecka D, Szwengiel A, Sulewska H, Kreft I, Gujska E, Walkowiak J. The Content of Dietary Fibre and Polyphenols in Morphological Parts of Buckwheat (Fagopyrum tataricum). Plant Foods Hum Nutr. 2018 Mar;73(1):82-88. doi: 10.1007/s11130-018-0659-0. PubMed 29435700 ↗
  • Caputo M, Bona E, Leone I, Sama MT, Nuzzo A, Ferrero A, Aimaretti G, Marzullo P, Prodam F. Inositols and metabolic disorders: From farm to bedside. J Tradit Complement Med. 2020 Mar 24;10(3):252-259. doi: 10.1016/j.jtcme.2020.03.005. eCollection 2020 May. PubMed 32670820 ↗
  • Wieslander G, Fabjan N, Vogrincic M, Kreft I, Janson C, Spetz-Nystrom U, Vombergar B, Tagesson C, Leanderson P, Norback D. Eating buckwheat cookies is associated with the reduction in serum levels of myeloperoxidase and cholesterol: a double blind crossover study in day-care centre staffs. Tohoku J Exp Med. 2011 Oct;225(2):123-30. doi: 10.1620/tjem.225.123. PubMed 21931228 ↗
  • Nishimura, M., Ohkawara, T., Sato, Y., Satoh, H., Suzuki, T., Ishiguro, K., ... & Nishihira, J. (2016). Effectiveness of rutin-rich Tartary buckwheat (Fagopyrum tataricum Gaertn.)'Manten-Kirari'in body weight reduction related to its antioxidant properties: A randomised, double-blind, placebo-controlled study. Journal of Functional Foods, 26, 460-469. https://doi.org/10.1016/j.jff.2016.08.004
  • Del Bo' C, Bernardi S, Marino M, Porrini M, Tucci M, Guglielmetti S, Cherubini A, Carrieri B, Kirkup B, Kroon P, Zamora-Ros R, Liberona NH, Andres-Lacueva C, Riso P. Systematic Review on Polyphenol Intake and Health Outcomes: Is there Sufficient Evidence to Define a Health-Promoting Polyphenol-Rich Dietary Pattern? Nutrients. 2019 Jun 16;11(6):1355. doi: 10.3390/nu11061355. PubMed 31208133 ↗
  • Perlmutter A, Bland JS, Chandra A, Malani SS, Smith R, Mendez TL, Dwaraka VB. The impact of a polyphenol-rich supplement on epigenetic and cellular markers of immune age: a pilot clinical study. Front Nutr. 2024 Nov 18;11:1474597. doi: 10.3389/fnut.2024.1474597. eCollection 2024. PubMed 39628466 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05234203
Lead sponsor
Big Bold Health, PBC
Collaborators
TruDiagnostic
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Mar 25, 2022
Primary completion
Oct 7, 2022
Completion
Oct 7, 2022
Last update
Dec 6, 2022

Study contacts

Jeffrey S Bland, Ph.D
principal investigator · Big Bold Health
Austin D Perlmutter, MD
study director · Big Bold Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Immune System Diseases →

Start the discussion